CE Mark Granted

NovoCure Limited's NVCR portable medical device, Option Pax, has received the CE mark for treating adult patients with locally advanced pancreatic cancer of exocrine origin. This approval in Europe is concomitant with gemcitabine and nab‑paclitaxel (gem/nab‑pac) and aligns with guideline recommendations. The company plans to initiate the launch of Option Pax in Europe, starting with Germany, following earlier FDA approval for the device‑drug combination.